Chemoimmunotherapy Less Safe, Efficacious in Younger ES-SCLC Population
Results from a retrospective study showed that chemoimmunotherapy did not prolong survival vs chemotherapy in a younger ES-SCLC population.
Previous Post
Electronic Health Record Study Finds No Significant Cardiovascular Risk With Triptan Use for Migraine
Next Post
Collaboration Brings “Excitement” to Novel Cancer Therapy Development
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago